You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 937 Post-immunotherapy survivorship in advanced melanoma (aMEL): routine versus symptom-based imaging surveillance, a retrospective review in a large integrated healthcare network, Kaiser Permanente Northern California (KPNC)

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Education and Treatment Management
937 Post-immunotherapy survivorship in advanced melanoma (aMEL): routine versus symptom-based imaging surveillance, a retrospective review in a large integrated healthcare network, Kaiser Permanente Northern California (KPNC)
Free

Authors

Citation

Kavecansky J, Xu R, Tucker L, et al
937 Post-immunotherapy survivorship in advanced melanoma (aMEL): routine versus symptom-based imaging surveillance, a retrospective review in a large integrated healthcare network, Kaiser Permanente Northern California (KPNC)
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0937

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.